title: Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
abstract: OBJECTIVE
  Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes.
  
  
  METHODS
  Ten subjects managed with continuous subcutaneous insulin infusion were enrolled. In addition to basal insulin, subjects received five randomized treatments: placebo, prandial insulin, 50 mg RE, 150 mg RE, and mg RE 500.
  
  
  RESULTS
  Adverse events and incidence of hypoglycemia with RE did not differ from placebo and prandial insulin groups. RE significantly increased urine glucose excretion and reduced the rise in plasma glucose concentration after oral glucose. RE reduced incremental adjusted weighted mean glucose (0-4 h) values by 42-49 mg/dL and mean glucose (0-10 h) by 52-69 mg/dL.
  
  
  CONCLUSIONS
  RE can be safely administered with insulin in type 1 diabetes and reduces plasma glucose concentrations compared with placebo.
authors.affiliation: Medicine Service, Veterans Administration Medical Center, San Diego, CA, USA.
authors.forename: Sunder
authors.initials: S
authors.lastname: Mudaliar
authors.forename: Debra A
authors.initials: DA
authors.lastname: Armstrong
authors.forename: Annie A
authors.initials: AA
authors.lastname: Mavian
authors.forename: Robin
authors.initials: R
authors.lastname: O'Connor-Semmes
authors.forename: Patricia K
authors.initials: PK
authors.lastname: Mydlow
authors.forename: June
authors.initials: J
authors.lastname: Ye
authors.forename: Elizabeth K
authors.initials: EK
authors.lastname: Hussey
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Nunez
authors.forename: Robert R
authors.initials: RR
authors.lastname: Henry
authors.forename: Robert L
authors.initials: RL
authors.lastname: Dobbins
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; D007328:Insulin; D011720:Pyrazoles; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C532127:remogliflozin etabonate